文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

巴西登革热疫苗真实世界安全性:药物警戒研究

Real-world safety of dengue vaccines in Brazil: A pharmacovigilance study.
PubMed 文献 · Vaccine · 2026-10-03

巴西全国回顾性药物警戒研究分析了截至2026年6月报告的47,666例登革热疫苗接种后不良事件(AEFI)或免疫差错记录。其中严重AEFI 525例(1.1%),非严重AEFI 43,043例(90.3%),免疫差错4,098例(8.6%)。登革热疫苗总体安全性良好,严重事件占比小,但需持续监测罕见信号并减少可预防的免疫差错。

要点

  • 严重AEFI仅占报告事件的1.1%,总体安全性良好。
  • 免疫差错占8.6%,主要为接种年龄不当、剂次间隔缩短和接种途径错误。
  • 2026年登革热疫苗接种活动扩大期间报告率上升。

核心结论

  • 登革热疫苗显示良好的安全性,严重不良事件仅占报告事件的小部分。
  • 结果支持登革热疫苗接种规划的实施,同时强调持续监测以识别罕见安全信号并减少可预防的免疫差错。

研究设计与样本

  • 全国性回顾性观察研究,使用巴西卫生部截至2026年6月报告的登革热疫苗相关AEFI记录。
  • 共纳入47,666名报告AEFI或免疫差错的个体,AEFI按国家监测标准分为严重与非严重,免疫差错单独分析。

主要发现

  • 47,666名个体中,525人(1.1%)经历至少一次严重AEFI,43,043人(90.3%)报告非严重AEFI,4,098人(8.6%)被归类为免疫差错。
  • Butantan-DV接种者中最常见的严重AEFI为皮肤表现、中枢神经系统症状和肌痛或关节痛。
  • 其他登革热疫苗接种者中以皮肤表现、过敏反应或支气管痉挛及呼吸道症状为主。
  • 非严重AEFI主要为皮疹、头痛和瘙痒。
  • 免疫差错主要与接种年龄不当、剂次间隔缩短和接种途径错误有关,2026年接种活动扩大期间报告率上升。

临床怎么用

  • 在登革热疫苗接种规划中应持续开展上市后安全性监测以识别罕见安全信号。
  • 应针对接种年龄、剂次间隔和接种途径等环节加强管理以减少可预防的免疫差错。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The expansion of dengue vaccination strategies in Brazil, including the introduction of the Butantan dengue vaccine (DV), has reinforced the importance of post-marketing safety surveillance. We aimed to characterize reporting patterns of adverse events following immunization (AEFIs) and immunization errors associated with dengue vaccines in Brazil. METHODS: We conducted a nationwide retrospective observational study using records of AEFIs associated with dengue vaccines reported to the Brazilian Ministry of Health through June 2026. AEFIs were classified as serious or non-serious according to national surveillance criteria, and immunization errors were analyzed separately. RESULTS: Among 47,666 individuals with reported AEFIs or immunization errors following dengue vaccination, 525 (1.1%) experienced at least one serious AEFI, 43,043 (90.3%) reported non-serious AEFIs, and 4098 (8.6%) were classified as immunization errors. Serious AEFIs were uncommon across vaccine platforms. Among recipients of Butantan-DV, the most frequent serious AEFIs were skin manifestations, central nervous system symptoms, and myalgia or arthralgia. Among recipients of other dengue vaccines, skin manifestations, anaphylaxis or bronchospasm, and respiratory symptoms predominated. Non-serious AEFIs were mainly exanthema, headache, and pruritus. Immunization errors were primarily related to inappropriate age at vaccination, shortened intervals between doses, and incorrect routes of administration. Reporting rates increased during the expansion of dengue vaccination activities in 2026. CONCLUSIONS: In this nationwide pharmacovigilance study, dengue vaccines demonstrated a favorable safety profile, with serious adverse events accounting for only a small proportion of reported events. These findings support the implementation of dengue vaccination programs while reinforcing the importance of ongoing surveillance to identify rare safety signals and reduce preventable immunization errors.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Boschiero MN, Sansone NMS, Marson FAL, et al. Real-world safety of dengue vaccines in Brazil: A pharmacovigilance study. Vaccine. 2026. PMID: 42828936. doi:10.1016/j.vaccine.2026.129178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。